Table 11.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Heart Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	2,340	2,363	2,343	2,293	2,348	2,188	2,199	2,202	2,155	2,055
Tx With Immunosuppression Info	2,328	2,306	2,051	2,267	2,322	2,139	2,147	2,152	2,117	1,984
No Induction Drugs Recorded	64.1%	64.9%	68.7%	70.2%	70.6%	65.7%	62.8%	56.4%	55.1%	52.9%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	16.0%	16.8%	17.0%	17.9%	16.9%	12.0%	9.4%	7.7%	7.0%	7.7%
OKT3	20.1%	18.7%	14.6%	12.4%	9.9%	11.1%	8.7%	8.6%	5.4%	4.5%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	2.5%	6.9%	10.7%	16.2%	13.0%
Zenapax	0.0%	0.0%	0.0%	0.0%	2.9%	7.2%	8.8%	13.4%	11.4%	14.8%
Simulect	0.0%	0.0%	0.0%	0.0%	0.2%	2.5%	5.1%	5.2%	6.9%	9.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.